Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Runzhi Huang, Zehui Sun, Shuyuan Xian, Dianwen Song, Zhengyan Chang, Penghui Yan, Jie Zhang, Huabin Yin, Zixuan Zheng, Peng Hu, Zhenyu Li, Dan Huang, Yihan Liu, Chenyang Jiang, Man Li, Siqi Li, Tong Meng, Daoke Yang & Zongqiang Huang. (2022) The role of toll-like receptors (TLRs) in pan-cancer. Annals of Medicine 54:1, pages 1918-1937.
Read now
Read now
Andrea Aiello, Anna D’Ausilio, Roberta Lo Muto, Francesca Randon & Luca Laurenti. (2017) Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy. Journal of Market Access & Health Policy 5:1.
Read now
Read now
Leslie J. Crofford, Lindsay E. Nyhoff, Jonathan H. Sheehan & Peggy L. Kendall. (2016) The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Review of Clinical Immunology 12:7, pages 763-773.
Read now
Read now
Xin Cao, L. Jeffrey Medeiros, Yi Xia, Xiaoxiao Wang, Sheeba K. Thomas, Sanam Loghavi, Xin Li, Jatin J. Shah, Steven A. Gustafson, Donna M. Weber, Roberto N. Miranda, Zijun Y. Xu-Monette, Robert Z. Orlowski & Ken H. Young. (2016) Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia & Lymphoma 57:5, pages 1104-1113.
Read now
Read now
Articles from other publishers (9)
M.F.A. Karel, B.M.E. Tullemans, G. D'Italia, T.P. Lemmens, T.A.M. Claushuis, M.J.E. Kuijpers & J.M.E.M. Cosemans. (2022) The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. Thrombosis Research 212, pages 72-80.
Crossref
Crossref
Udhayvir Singh Grewal, Sahith Reddy Thotamgari, Aakash Rajendra Sheth, Shiva Jashwanth Gaddam, Javaria Ahmad, Kavitha Beedupalli & Paari Dominic. (2021) Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis. International Journal of Cardiology 344, pages 186-189.
Crossref
Crossref
Suman Rao, Deepak Gurbani, Guangyan Du, Robert A. Everley, Christopher M. Browne, Apirat Chaikuad, Li Tan, Martin Schröder, Sudershan Gondi, Scott B. Ficarro, Taebo Sim, Nam Doo Kim, Matthew J. Berberich, Stefan Knapp, Jarrod A. Marto, Kenneth D. Westover, Peter K. Sorger & Nathanael S. Gray. (2019) Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology 26:6, pages 818-829.e9.
Crossref
Crossref
Tianfeng Li, Yi Deng, Yu Shi, Ruijun Tian, Yonglong Chen, Lin Zou, Julhash U. Kazi, Lars Rönnstrand, Bo Feng, Sun On Chan, Wai Yee Chan, Jianmin Sun & Hui Zhao. (2018) Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37:47, pages 6180-6194.
Crossref
Crossref
Irene Kim, Gordon Wu, Ning-ning Chai, Andrew S. Klein & Stanley Jordan. (2017) Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization. Transplant Immunology 45, pages 59-64.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
609
637
.
Claudia Walliser, Elisabeth Hermkes, Anja Schade, Sebastian Wiese, Julia Deinzer, Marc Zapatka, Laurent Désiré, Daniel Mertens, Stephan Stilgenbauer & Peter Gierschik. (2016) The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. Journal of Biological Chemistry 291:42, pages 22136-22148.
Crossref
Crossref
Sikander Ailawadhi, Aneel Paulus & Asher Chanan-Khan. (2016) Preclinical models of Waldenstr?m's macroglobulinemia and drug resistance. Best Practice & Research Clinical Haematology 29:2, pages 169-178.
Crossref
Crossref
Tiantao Gao, Lidan Zhang, Yongxia Zhu, Xuejiao Song, Qiang Feng, Qian Lei, Suxia Shi, Hongxia Deng, Menghua Xiong, Xinyu You, Weiqiong Zuo, Li Liu, Cuiting Peng, Ningyu Wang, Tinghong Ye, Yong Xia & Luoting Yu. (2016) ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth. RSC Adv. 6:34, pages 28512-28521.
Crossref
Crossref